Advertisement
Advertisement
MYGN
Myriad Genetics Inc
5.92
USDSponsored
-0.37
-5.88%
Nov 06, 15:59 UTC -5
Closed
After-Market
5.90
-0.02
-0.27%
Myriad Genetics Inc (MYGN) Earnings
MYGN Earnings Reports
Positive Surprise Ratio
MYGN beat 19 of 24 last estimates.
79%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$200.04M
/-$0.18
Implied change from Q3 26 (Revenue/ EPS)
-1.31%
/+63.64%
Implied change from Q4 25 (Revenue/ EPS)
-4.65%
/-550.00%
Myriad Genetics Inc earnings per share and revenue
On Nov 04, 2026, MYGN reported earnings of -0.11 USD per share (EPS) for Q3 26, beating the estimate of -0.20 USD, resulting in a 46.08% surprise. Revenue reached 202.70 million, compared to an expected 195.16 million, with a 3.87% difference. The market reacted with a +4.49% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.18 USD, with revenue projected to reach 200.04 million USD, implying an increase of 63.64% EPS, and decrease of -1.31% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Myriad Genetics Inc's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Myriad Genetics Inc reported EPS of -$0.11, beating estimates by 46.08%, and revenue of $202.70M, 3.87% above expectations.
How did the market react to Myriad Genetics Inc's Q3 2026 earnings?
The stock price moved up 4.49%, changed from $6.02 before the earnings release to $6.29 the day after.
When is Myriad Genetics Inc expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Myriad Genetics Inc's next earnings report?
Based on --
analysts, Myriad Genetics Inc is expected to report EPS of -$0.18 and revenue of $200.04M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.